U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

In what could be a revolutionary stride in cancer care, scientists are exploring metabolism-targeting injections as a ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The World Health Organization will convene a meeting of its Emergency Committee next week to determine whether mpox remains a ...

Semaglutide, the GLP-1 drug that Novo sells under the brand names Ozempic for diabetes and Wegovy for weight loss, has made ...

FAT jabs such as Ozempic and Wegovy could be “game changers” in tackling bowel cancer within five years, researchers have claimed Evidence has already shown that injections of the weight-loss drugs ...

Metabolism-targeting injections could pave the way for a new treatments, detection and prevention of bowel cancer ...

Rising numbers of people are needing hospital treatment for side effects from weight loss injections and it may be affecting ...

Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.

The first new guidelines in 10 years from the American Stroke Association for people and doctors reflect a better ...